Pages that link to "Q57785361"
The following pages link to Protective Immunity Against Trypanosoma cruzi Infection in a Highly Susceptible Mouse Strain After Vaccination with Genes Encoding the Amastigote Surface Protein-2 and Trans-Sialidase (Q57785361):
Displaying 34 items.
- Relevance of the diversity among members of the Trypanosoma cruzi trans-sialidase family analyzed with camelids single-domain antibodies (Q33379102) (← links)
- Identification of novel vaccine candidates for Chagas' disease by immunization with sequential fractions of a trypomastigote cDNA expression library (Q33402005) (← links)
- Intranasal vaccinations with the trans-sialidase antigen plus CpG Adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges. (Q33675887) (← links)
- A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease (Q33760119) (← links)
- Co-Administration of a Plasmid DNA Encoding IL-15 Improves Long-Term Protection of a Genetic Vaccine against Trypanosoma cruzi (Q33847435) (← links)
- CD8(+) T cell-mediated immunity during Trypanosoma cruzi infection: a path for vaccine development? (Q33914939) (← links)
- Subdominant/cryptic CD8 T cell epitopes contribute to resistance against experimental infection with a human protozoan parasite. (Q33968196) (← links)
- CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2. (Q34034104) (← links)
- Recombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruzi (Q34635043) (← links)
- TcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice (Q34651261) (← links)
- Biological and immunological characterization of recombinant Yellow Fever 17D Viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+T cell epitope at two distinct regions of the genome (Q34732681) (← links)
- Heterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruzi (Q34931648) (← links)
- Anatomical route of invasion and protective mucosal immunity in Trypanosoma cruzi conjunctival infection. (Q35073839) (← links)
- Antigen targeting to dendritic cells allows the identification of a CD4 T-cell epitope within an immunodominant Trypanosoma cruzi antigen (Q35095495) (← links)
- The Immune Response to Trypanosoma cruzi: Role of Toll-Like Receptors and Perspectives for Vaccine Development (Q35838023) (← links)
- Parasite-induced chronic inflammation is not exacerbated by immunotherapy before or during Trypanosoma cruzi Infection (Q36097139) (← links)
- Induction of cardiac autoimmunity in Chagas heart disease: a case for molecular mimicry (Q36385476) (← links)
- Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease (Q36844914) (← links)
- DNA Vaccines against Protozoan Parasites: Advances and Challenges (Q36915067) (← links)
- Chagas' disease: an update on immune mechanisms and therapeutic strategies (Q37310959) (← links)
- Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination. (Q37355936) (← links)
- The endless race between Trypanosoma cruzi and host immunity: lessons for and beyond Chagas disease (Q37788829) (← links)
- Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate (Q39007706) (← links)
- LFA-1 Mediates Cytotoxicity and Tissue Migration of Specific CD8+ T Cells after Heterologous Prime-Boost Vaccination against Trypanosoma cruzi Infection. (Q42682937) (← links)
- Distinct kinetics of effector CD8+ cytotoxic T cells after infection with Trypanosoma cruzi in naive or vaccinated mice. (Q43255101) (← links)
- Strain-specific protective immunity following vaccination against experimental Trypanosoma cruzi infection. (Q43550922) (← links)
- Efficient protective immunity against Trypanosoma cruzi infection after nasal vaccination with recombinant Sendai virus vector expressing amastigote surface protein-2. (Q43591184) (← links)
- Protective immunity against Trypanosoma cruzi (Q51890237) (← links)
- Evaluation of immune responses raised against Tc13 antigens of Trypanosoma cruzi in the outcome of murine experimental infection (Q51969941) (← links)
- Cross-priming of long lived protective CD8+ T cells against Trypanosoma cruzi infection: importance of a TLR9 agonist and CD4+ T cells. (Q51973677) (← links)
- Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of Trypanosoma cruzi infection in mice (Q58842209) (← links)
- Immune system pathogenesis is prevented by the neutralization of the systemic trans-sialidase from Trypanosoma cruzi during severe infections (Q58855148) (← links)
- Re-circulation of lymphocytes mediated by sphingosine-1-phosphate receptor-1 contributes to resistance against experimental infection with the protozoan parasite Trypanosoma cruzi (Q83548592) (← links)
- CXCR3 chemokine receptor guides Trypanosoma cruzi-specific T-cells triggered by DNA/adenovirus ASP2 vaccine to heart tissue after challenge (Q92251637) (← links)